Latest Blog Posts Tagged "LRRK2"
December 08, 2017
Denali Therapeutics, which is testing a first-in-human LRRK2 inhibitor, filed the biggest biotech IPO of 2017.
August 15, 2017
The launch of key Parkinson's protein LRRK2 into space inspires a Patient Council member's actions in pursuit of a cure and his daughter's curiosity around research.
July 20, 2017
MJFF is partnering to send LRRK2 protein to the International Space Station to grow larger LRRK2 crystals, which can help develop therapies. Michael J. Fox shares a special message on this project.
April 07, 2017
A recent study, funded in part by The Michael J. Fox Foundation, examined the role of LRRK2 in the immune cells in blood of people with sporadic PD and healthy individuals.
February 06, 2017
Barbara and Jay Robinson discuss their decision to participate in Parkinson's genetics research.
November 22, 2016
For Jessica O'Brien, Facebook was a place to post pictures of her dogs, until it became a starting point in her journey to understand Parkinson's disease.
October 26, 2016
An MJFF-funded study identified a new factor that may affect age of PD onset in individuals who carry a LRRK2 mutation.
October 11, 2016
In this podcast, MJFF staff scientist Marco Baptista, PhD, discusses the genetics and biology of LRRK2 and the role of the Foundation in advancing development of LRRK2 therapeutics.
September 08, 2016
A new study, funded in part by MJFF, identified a potential common link across different causes of Parkinson's.
August 25, 2016
With confidence from MJFF-led studies, Denali Therapeutics today announced it has licensed LRRK2 inhibitor compounds from Genentech.